The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | AARON trial: relatlimab, nivolumab and 5-azacitidine combination in R/R AML
In this video, Veit Buecklein, MD, LMU Munich, Munich, Germany, shares some insights into the AARON trial (NCT04913922), which is evaluating whether combining two immune checkpoint inhibitors (ICIs), relatlimab and nivolumab, with hypomethylating agent (HMA)-based therapy can improve outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; Pfizer: Research Funding, Speakers Bureau; Miltenyi Biotech: Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; Amgen: Honoraria.
